RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $15
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $14 to $15.
RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $14 to $15.